Armistice Capital’s SELLAS Life Sciences SLS Stock Holding History

Armistice Capital’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-820,000	Closed	-$869K	–	408
2023 Q4	$869K	Buy	+820,000	New	+$887K	0.01%	180

Other funds holding SLS

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OCG

Opus Capital Group Cincinnati, Ohio $1.03B AUM 20.67% 1-Year Est. Return

Equitable Holdings New York $16.7B AUM 24.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

PFG

Prosperity Financial Group San Ramon, California $323M AUM 35.79% 1-Year Est. Return

Armistice Capital's SLS Position: Q1 2024 in Review

Armistice Capital sold out of SELLAS Life Sciences (SLS) in Q1 2024, closing a stake of 820,000 shares — an estimated $869K sold.

Armistice Capital first reported a position in SLS in Q4 2023 and held it in 1 quarter. The position peaked at $869K in Q4 2023. 30 funds tracked by Wall St. Rank hold SLS as of Q1 2024.

Armistice Capital reported no remaining SELLAS Life Sciences position as of Q1 2024 after selling out during the quarter.
Armistice Capital sold 820,000 SELLAS Life Sciences shares in Q1 2024, an estimated $869K.
Armistice Capital first reported a position in SELLAS Life Sciences in Q4 2023 and held it in 1 quarter.
Armistice Capital's SELLAS Life Sciences position peaked at $869K in Q4 2023.
30 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2024.

Based on Armistice Capital's 13F filing for Q1 2024, filed 15 May 2024.